# Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

> **NCT04968379** · PHASE2 · WITHDRAWN · sponsor: **American Regent, Inc.**

## Conditions studied

- Iron Deficiency, Anaemia

## Interventions

- **DRUG:** Ferric carboxymaltose

## Key facts

- **NCT ID:** NCT04968379
- **Lead sponsor:** American Regent, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-21
- **Primary completion:** 2024-10-08
- **Final completion:** 2024-12-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficult to recruit and enroll patients for this study in a reasonable amount of time.
- **Last updated:** 2023-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04968379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04968379, "Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04968379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*